阿尔凯默斯 ALKS 深 沪
等待开盘 05-12 09:30:00 美东时间
35.57
+0.590
+1.69%
华盛通- 最 高36.60
- 今 开35.22
- 成交量 91.27万股
- 最 低 34.8715
- 昨 收 34.98
- 总市值 583.35万
- 52周最高 36.60
- 市盈率 静 --
- 换手率 556.50%
- 52周最低 25.165
- 委 比 54.10%
- 总股本 0.00亿
- 历史最高 80.71
- 量 比 0.56
- 振 幅 4.94%
- 历史最低 1.10
- 每 手 1
- 风险率 2.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alkermes Appoints Blair Jackson As CEO Succeeding Richard Pops, Effective August 1
— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes —— Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief
02-25 19:59
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.
2025-11-15 00:37
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
从产品出口到标准协同：新能源汽车出海的模式跃迁
原标题：从产品出口到标准协同：新能源汽车出海的模式跃迁 中国新能源汽车出口正从规模扩张转向质量跃升。核心突破在于国际标准认证体系的打通，动力电池通过欧盟EC...
2025-08-12 17:04
阿尔凯默斯盘中异动 股价大涨5.01%
北京时间2024年10月12日02时35分，阿尔凯默斯（ALKS.us）股票出现波动，股价急速拉升5.01%。截至发稿，该股报28.74美元/股，成交量79.2642万股，换手率0.48%，振幅5.26%。 最近的财报数据显示，该股实现营业收入3.99亿美元，净利润94.66百万美元，每股收益0.54美元，毛利3.36亿美元，市盈率16.79倍。 机构评级方面，在所有14家参与评级的机构中，57%的券商给予买入建议，36%的券商给予持有建议，7%的券商给予卖出建议。 阿尔凯默斯股票所在的制药行业中，整体涨幅为1.30%。其相关个股中，Cyclo Therapeutics Inc C/Wts 1...
2024-10-12 02:35
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Across the recent three months, 6 analysts have shared their insights on Alkerm...
2024-09-17 05:01
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $48 price target.
2024-09-16 23:19
Alkermes Initiates Phase 2 Trial of ALKS 2680 to Treat Narcolepsy Type 2
09:01 AM EDT, 08/22/2024 (MT Newswires) -- Alkermes (ALKS) said Thursday it initiated a phase 2 Vibrance-2 study to evaluate the safety and efficacy of ALKS 2680, a once-daily potential treatment for narcolepsy, in comparison to placebo in adult patients with narcolepsy type 2. Narcolepsy is a neuro...
2024-08-22 21:01
